Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
Posted on: Wednesday, 29 April 2009, 02:39 CDT
"We are very pleased with the outcome of this study, which is the first
large study to ever demonstrate the efficacy of house dust mites allergen in
treating perennial allergic rhinitis. Furthermore, the unexpected quick onset
of action and the good safety profile are addressing the needs of patients
with moderate to severe forms of the disease. This study will be pivotal in
the European registration process of our house dust mites sublingual tablet,
and the basis for further developments in our program" states
Stallergenes has been conducting a phase IIb/III clinical trial, with a
sublingual tablet in adults suffering from moderate to severe persistent
allergic rhinitis to house dust mites, including 509 patients, over seven
countries, with a full year of treatment from January to
The two treated groups have demonstrated a highly significant statistical difference on the primary endpoint versus the placebo group (p less than or equal to 0.0136), with no difference between the two treated groups. In the different groups, use of rescue medication was allowed throughout the period. The adjusted average symptom score has been improved by 20% in both treated groups. In particular, the nasal congestion score has been improved by 40% (median) and the nasal pruritus by 32% (median). The safety profile has been highly satisfactory.
For the same level of efficacy, the 300 IR tablet has been selected.
Furthermore, the onset of action was achieved from the 4th month of treatment, meaning that the difference between the placebo and the treated groups was statistically significant, the treatment effect being maintained at the same level up to the end of the study.
The quality of life has been statistically improved and the proportion of symptom-controlled days increased by 52%.
The study will be pursued over 1 year on an observational basis in accordance with protocol.
"The conduct of clinical trials in perennial allergic rhinitis is a major
challenge. The outcomes of the VO57.07 are clearly good and consistent,
clinically important and relevant", said Prof.
About House Dust Mites Allergic Rhinitis
In
About the Stalair(R) Development Program
According to World Health Organization (WHO) estimates, 20 to 25% of the world's population currently suffers from respiratory allergic symptoms (rhinoconjunctivitis, rhinitis and/or asthma). By 2020, 50% of the world's population may be affected by at least one allergy according to the ISAAC study. For nearly 15 to 20% of patients currently suffering from severe allergic rhinitis and rhinoconjunctivitis, their condition is not adequately controlled and has an adverse effect on their quality of life.
Sublingual desensitization therapy is fully recognized and coded by international consensus (ARIA), under the aegis of WHO. Supported by a high level of evidence, this consensus recommends the use of desensitization therapy when the patient's allergy is not adequately controlled by symptomatic treatments, which act on the symptoms of the condition without addressing its cause.
To date, desensitization therapy is the only treatment option that treats the immunological causes of allergies and modifies the natural course of the disease, preventing it from worsening.
Since 2003, Stallergenes has been running the Stalair(R) program, which aims to address the immunological cause of respiratory allergies with EBM-documented, registered allergen tablets. This program consists in the development of tablets for five of the main allergens triggering more than 80% of allergies: grass pollens, house dust mites, birch pollen, ragweed pollen, Japanese cedar pollen. The entire program is in the clinical development stage and is proceeding according to schedule.
The first tablet from the program, Oralair(R) (a desensitization tablet
for grass pollens) is available in
About Stallergenes
Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis, rhinitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 21% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.
In 2008, Stallergenes had a turnover of
SOURCE Stallergenes
Source: PR Newswire
Related Articles
- Meda Introduces EDLUAR(TM), the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication, Zolpidem Tartrate
- Asthma Sufferers Wasting Money in Dust Mites Battle
- Dust Mites: The Tiny Critters Can Torment
- Replacing Old Mattresses Cuts Dust Mites
- Replacing an Old Mattress and Adding More Ventilation Reduces Bedroom Dust Mites
- Dust Mites, Diet Don't Affect Asthma
- HEPA Vacuums Unlikely to Curb Dust Mite Exposure
- Mom's dust mite exposure shared with her fetus
- Season of birth linked to dust-mite asthma
 |
 |
User Comments (0)
RSS Feeds